«Our study shows that genotyping of CYP2C19 could be of considerable clinical value in individualising doses of
escitalopram so that a better all - round antidepressive effect could be achieved for the patients,» says Professor Magnus Ingelman - Sundberg at Karolinska Institutet's Department of Physiology and Pharmacology who led the study together with Professor Espen Molden.